[Clinical study of bugu shengsui capsule in treating primary osteoporosis with kidney-yang deficiency syndrome].
OBJECTIVE
To assess the effect of Bugu Shengsui capsule (BGSSC) in treating primary osteoporosis.


METHODS
Using double energy X-ray bone densimeter and radioimmunoassay (RIA), the effect of BGSSC in treating primary osteoporosis (OP) with Kidney-Yang Deficiency syndrome.


RESULTS
The clinical markedly effective and total effective rates of BGSSC were 46% and 82%, respectively. The rate of TCM group is significantly higher than that of the control group (Vitamin D plus calcium). BGSSC could improve bone mineral density by the verification of double energy X-ray bone dansity (DEXA). It could also increase the level of serum calcitonin, luteinizing hormone and calcium, decrease the activity of parathyroid hormone.


CONCLUSIONS
The effects of BGSSC on primary OP included increasing patient's bone mineral density, depressing bone resorption and decreasing bone loss.
D000368:Aged; D015519:Bone Density / Q000187:drug effects; D002214:Capsules; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D016711:Yang Deficiency / Q000188:drug therapy*